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A RELIABLE method for selecting the cancer chemotherapeutic drugs most
likely to be clinically effective in particular patients is needed. The in vitro
response of human tumour cells to cytotoxic agents has often been examined but
such studies have so far failed to give results of practical clinical use. A method
for examining the response of human tumours to cytotoxic drugs under less
artificial conditions, in an in vivo system, would be preferable in many respects
and might yield more valid results.
Billingham, Ferrigan and Silvers (1960) showed that the cheek pouch of the
golden hamster possesses immunological privilege, in the sense that grafts of
homologous and heterologous tissue will often survive for many weeks at this site.
Handler, Davis and Sommers (1956) and Patterson, Patterson and Chute (1957)
reported that a considerable proportion of human tumours will grow in the wall
of the cheek pouch for short periods. It was therefore thought that the hamster
cheek pouch might be a suitable transplantation site for human tumour tissue
derived from biopsy specimens, with a view to examining the sensitivities of the
tumour cells to different cytotoxic drugs.
However, before the results of cytotoxic studies on human tumour transplants
can be used to predict the clinical sensitivities oftumours, it is necessary to ensure
that the normal response of tumour cells to cytotoxic drugs is not altered by their
heterologous transplantation to the hamster. Observations by Smith (1968)
suggest that human tumour cells may retain their specific sensitivities while
growing in the wall ofthe cheek pouch, but a direct comparison ofthe response of
cells to drugs in the hamster and in the natural tumour host has not yet been made.
In the present study, therefore, the effects ofcytotoxic agents on a murine tumour
growing in the rat and at the hamster cheek pouch have been examined and
compared.
METHODS
The Walker 256 rat carcinosarcoma was chosen for the studv because its rapid
and reliable growth in the rat suggested that it would be suitable for short-term
cytotoxic studies in the hamster. The response of this tumour to the alkylat-
ing agent nitrogen mustard (di (2 chloroethyl) methylamine hydrochloride),
and to the antimetabolite methotrexate was compared in the rat and in the
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Rats
Adult male Wistar rats were used. Tumour was implanted by subcutaneous
injection of 0-5 ml. of a freshly-prepared cell suspension to each flank.
The dosages of nitrogen mustard used were 0*2 and 0.4 mg./kg./day. These
were calculated to be approximately equivalent in effect to 0f25 and 05 mg./kg./
day in the hamster using the criteria of Freireich et al. (1966). Each dose was
administered to three rats (six tumours). Three rats (six tumours) were used as
controls and received no drugs. Rosenoer et al. (1966) have shown that inactive
drug solvents have no effect on the growth of the Walker 256 tumour, therefore
control animals received no injections.
The dosages of methotrexate used were 1.0 and 2-0 mg./kg./day. These were
calculated to be equivalent to 1-25 and 2-5 mg./kg./day in the hamster. Again
each dose was administered to three rats (six tumours), andthree rats (six tumours)
were used as controls.
The cytotoxic agents were given by single, daily, intraperitoneal injections for
seven successive days. Treatment was started on the third day after tumour
transplantation. At the end of the period of therapy, on the tenth day after
transplantation, the animals were killed and the tumours excised, weighed and
examined histologically. Changes in rat body weight were recorded.
Hamsters
Golden hamsters of either sex, 25-40 weeks old, and weighing 100-200 g. were
used. Walker 256 tumour tissue was obtained aseptically from donor rats about
one week after implantation. Fragments of tumour, approximately 1 cu. mm. in
size were transplanted to the cheek pouches of 24 hamsters. The Sanders (1963)
observation chamber, which enables cheek pouch grafts to be examined micro-
scopically in vivo, was used to observe the effect of the cytotoxic drugs on the
tumour transplants.
Three dosages of nitrogen mustard and methotrexate were used. These were
chosen because they were known to produce some inhibition of the Walker 256
tumour in the rat, yet lay below L.D.50 levels for the hamster. Each dose was
administered to three hamsters. Six hamsters were used as controls.
The drugs were administered by single, daily, intraperitoneal injections for
seven successive days. The first injection was given on the third day after
transplantation, by which time the tumour had usually obtained a complete blood
supply by ingrowth of cheek pouch blood vessels.
The transplants were examined and measured microscopically every 1-2 days.
It was not possible to estimate their volume because sufficiently accurate measure-
ments of tumour depth could not be obtained. Therefore, as the depth of each
implant remained almost constant within the rigid confines of the chamber, and
was always less than 0*5 mm., an estimate of tumour surface area (T.S.A.) was
used as the index of tumour size. This was defined as the area of tumour visible
on in vivo microscopy, and was measured with a micrometer eyepiece.
The time taken for each tumour to stop growing was noted, and the tumour
surface area was estimated at the start and at the end of treatment. Changes in
hamster body weight during this period were also recorded, due allowance being
made for the weight of the chamber (3 g.). After the course of cytotoxic therapy
the animals were killed and the tumour grafts were excised for histological
examination.
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RESULTS
Rats
All the rats which received the higher dosages ofnitrogen mustard and metho-
trexate died before the completion of the experiment. This was not unexpected
as the L.D.10 values for these agents in the rat are 0-25-0-5 mg./kg./day x 7 and
0-5-1-0 mg./kg./day x 7 respectively. Rats treated with the lower dosages of
both drugs lost body weight, and one (receiving methotrexate) died during the
experiment. Control animals showed a slight gain in weight.
Nitrogen mustard in a dose of 0-2 mg./kg./day inhibited tumour growth.
There was a significant difference (P < 0.02) between the weights of tumours in
treated and untreated control animals 10 days after implantation (Table I).
However, although tumour growth was inhibited, complete regression did not
occur, and histological examination revealed the presence of many apparently
viable cells.
TABLE I.-The Effect ofNitrogen Mustard on the Growth of Walker 256
Tumour* in the Rat
Untreated
controls Nitrogen mustard
Tumour weight 0-2 mg./kg./day x 7 0-4 mg./kg./day x 7
Animals Tumours (g.) 10 days after implantation
1-3 1 . 11 . 0-05 Rat died
2 . 1-2 . 0-04
4-6 3 03 0-01 Rat died
4 . 0-4 0-02
7-9 . 5 2- 8 . 001 Rat died
6 3-2 0-04
Total tumour weights . 9-0 . 0-2
Mean body-weight change . +2-0% . -12*0%
Significance of difference between tumour weights in control rats and rats receiving nitrogen
mustard (0*2 mg./kg. x 7), P < 0-02.
* Cell suspension used for implantation = 1500 cells/cu. mm.
Tumour growth was also significantly inhibited (P < 0.01) in rats treated with
1-0 mg./kg./day of methotrexate (Table II). But again complete regression did
not take place, and viable tumour cells were visible on histological examination.
It was concluded from these observations that nitrogen mustard and metho-
trexate, in dosages which are approximately equivalent to 0-25 mg./kg./day and
1-25 mg./kg./day respectively in the hamster, cause measurable inhibition, but not
complete regression, of the Walker 256 tumour in the rat.
Hamsters
Tumours in untreated control animals increased in size steadily during the
observation period. The mean percentage increase in tumour surface area of six
tumours from three until 10 days after transplantation was 1642% (Table III).
Nitrogen mustard produced measurable inhibition oftumour growth in treated
hamsters compared with untreated controls (Table IV). The degree of tumour
inhibition varied with the dose received. With dose levels of 0-5 and 1-0 mg./kg./
day, the tumours stopped growing on average seven and four days respectively
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TABLE II.-The Effect of Methotrexate on the Growth of Walker 256 Tumour*
in the Rat
Untreated
controls
Animals
10-12
13-15
16-18
Tumours
1
2
3
4
5
6
Total tumour weights
Mean body-weight change
Tumour weight
(g.)
9-6
10-5
13*7
5-6
4 0
50-6
+6-0%
Methotrexate
1 0mg./kg./day x 7 20 mg./kg./day x 7
10 days after implantation
Rat died Rat died
0 03
0 04
0 3
0-1
0 5
-9.0%
Rat died
Rat died
Significance of difference between tumour weights in control rats and rats receiving methotrexate
(1Omg./kg. x 7),P < 0-01.
* Cell suspension used for implantation = 2750 cells/cu. mm.
TABLE III.-The Growth of Cheek Pouch Grafts of Walker 256 Tumour in Untreated
Control Hamsters
Implant
diameters
at 3 days
(mm.)
. 2-0 x 2X0 .
. 2-0 x30 .
. 2*0 x 2-0 .
. 2-0 x 2*0 .
. 2-0 x 30
. 2-0 x 2-5 .
Tumour
surface
area at
3 days
(sq. mm.)
3-1
4.7
3*1
3*1
4-7
3 9
Tumour
Implant surface
diameters area at
at 10 days 10 days
(mm.) (sq. mm.)
6-5 x 7-5. 38-3
12-5 x 11-0. 108-0
8-0 x 7-5 47-1
8-0 x 80. 50-2
. 10-0 x 10-0. 78 5
. 10-5 x 10*0. 82 4
Increase in
T.S.A. (%)
1135
2198
1419
1519
1570
2012
Change in
body-weight
(%)
-3-6
+4-2
-6*8
+4-5
-6-1
Mean increase in T.S.A. = 1642%.
Mean change in body-weight = -0 3%.
after transplantation. A dose of 0*25 mg./kg./day, however, did not cause cessa-
tion of growth during the seven-day period of treatment.
Implants in hamsters treated with 0-25 mg./kg./day of nitrogen mustard
showed a mean percentage increase in tumour surface area of 1039% during cyto-
toxic therapy, and those in hamsters treated with 0*5 mg./kg./day an increase of
393%. Tumours in hamsters receiving 1.0 mg./kg./day showed marked evidence
ofregression by the end of the treatment period. Their edges became impossible
to define in vivo and accurate measurements oftumour size could not be obtained.
Similar results were obtained with methoxtrexate (Table V). Doses of 1*25,
2*5 and 5*0 mg./kg./day were used. The lowest dose did not cause cessation of
growth during the treatment period of seven days but with the higher doses the
tumours stopped growing on average nine and seven days after transplantation.
Implants in hamsters treated with 1*25 mg./kg./day of methotrexate showed
a mean percentage increase in tumour surface area of 532% during cytotoxic
therapy, and those in hamsters treated with 2*5 mg./kg./day an increase of 353%.
Tumours in hamsters receiving 5-0 mg./kg./day revealed evidence of regression by
the end of treatment and it was not possible to measure them accurately.
Number
1
2
3
4
5
6
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TABLE IV.-The Growth of Cheek Pouch Grafts of Walker 256 Tumour in Hamsters
Treated with Nitrogen MuXtard
Implant
diameters
at 3 days
Number (mm.)
7
8
9
10
11
12
Tumour
surface
area at
3 days
(sq. mm.)
Implant
diameters
at 10 days
(mm.)
Tumour
surface
area at
10 days
(sq. mm.)
Change in
Increase in body-weight
T.S.A. (%) (%)
Nitrogen mustard 0 25 mg./kg./day x 7
. 2-0 x 2-0 . 3-1 . 7 0 x 7-0 . 38-5 . 1142
. 30x2-0 . 4-7 . 9*0x8-5 . 60-1 1179
3*0 x 3 0 . 741 . 9 0 x 9 0 . 636 796
Mean increase in T.S.A. = 1039%; Mean change in body-weight = -5-4 4/.
Tumour continued to grow during treatment.
. 2-0 x 30.
. 2-5 x 2-0 .
. 2-0 x 2-0 .
Nitrogen mustard 0 5 mg./kg./day x 7
4.7 . 6-0x5-5 . 25-9
3 9 . 6-0 x 5-5 . 25-9
3-1 . 3.5 x 3 0 . 8-2
451
564
165
-2-2
-13-0
-1-0
-10-2
-9 6
-18-3
Mean increase in T.S.A. = 393%; Mean change in body-weight = -12- 7%.
Tumours stopped growing 7, 7, and 7 days after transplantation.
13
14
15
* 3 0 x 2-5 .
. 2-0 x 2-0 .
. 2-5 x 2-5 .
Nitrogen mustard 1 0 mg./kg./day x 7
5.9 . Impossible to measure due to regression
3 1 . Impossible to measure due to regression
4 9 . Impossible to measure due to regression
-16-3
-32 -4
-23-4
Mean change in body-weight = -24- 0%.
Tumours stopped growing 4, 4 and 5 days after transplantation.
TABLE V.-The Growth of Cheek Pouch Grafts of Walker 256 Tumour in Hamsters
Treated with Methotrexate
Implant
diameters
at 3 days
Number (mm.)
16
17
18
. 30 x 30 .
. 2-5 x 2-0 .
. 2-0 x 2-0 .
Tumour Tumour
surface Implant surface
area at diameters area at
3 days at 10 days 10 days
(sq. mm.) (mm.) (sq. mm.)
Methotrexate 1- 25 mg./kg./day x 7
7*1 . 8-0 x 6-0 . 37-7
3 9 . 6-0 x 5 0 . 23-6
3-1 . 6-0 x50 . 23-6
Change in
Increase in body-weight
T.S.A. (%) (%)
431
505
661
-8-0
+6-4
-2-3
Mean increase in T.S.A. = 532%; Mean change in body-weight = - 1-3%.
Tumours continued to grow during treatment.
Methotrexate 25 mg./kg./day x 7
3-9 . 5-5 x 5 0 . 21-6
3-1 . 4 0 x 4 0 . 12-6
2-4 . 3-5 x 3-5 . 9-6
454
306
300
-4-5
-6-5
-7-3
Mean increase in T.S.A. = 353%/; Mean change in body-weight = -6 - 1%.
Tumours stopped growing 9, 8, and 9 days after transplantation.
Methotrexate 5 0 mg./kg./day x 7
3- 9 . Impossible to measure due to regression
7- 1 . Impossible to measure due to regression
4 9 . Impossible to measure due to regression
-7-6
-7-4
-13-8
Mean change in body-weight = -9 - 6%.
Tumours stopped growing 6, 7, and 7 days after transplantation.
19
20
21
. 2-5 x 2-0 .
. 2-0 x 2-0 .
. 2-0 x 1X5 .
22
23
24
. 2-5 x 2-0 .
3 0 x 3 0
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Growth ofthe implants was readily visible on microscopy in vivo, and the time
when they stopped growing could also be recorded with certainty. It was not
possible, however, to assess quantitatively tn vivo the changes which took place
during tumour regression. During this process the implants did not shrink in
size by drawing in gradually from the periphery only; rather they regressed over
the whole of their extent with a resultant decrease in depth as well as of surface
area. This, and also the viability of the tumour cells within the implant, could
not be measured in vivo and had to be assessed by examination of fixed, stained
sections of the tumour.
Histological examination of the implants after the period of therapy showed
that those which had received the lowest dosages of both nitrogen mustard and
methotrexate consisted largely of viable tumour cells, though many dead cells
with pyknotic nuclei were also present. Implants treated with intermediate
dosages of the drugs consisted of sparsely scattered tumour cells, while those
receiving the highest dosages contained few or no recognisable tumour cells.
Untreated control implants, in contrast, were composed of densely-packed viable
cells, except in their centres where, as during growth of the tumour in the rat at
this stage, avascular necrosis was present.
It was concluded from these observations that both nitrogen mustard and
methotrexate have an inhibitory effect on the heterologous growth of the Walker
256 tumour in the hamster, and that the response of the transplanted tumour is
related to the dose of drug administered.
DISCUSSION
These results demonstrate that nitrogen mustard and methotrexate cause
measurable inhibition, but not complete regression, of the Walker 256 tumour in
the rat when given in dosages which are approximately equivalent to 025 mg./
kg./day and 1-25 mg./kg./day respectively in the hamster. This effect is the same
as that produced by the drugs in comparable dosages on the tumour growing
heterologously at the hamster cheek pouch. Therefore it is evident that the
response to nitrogen mustard and methotrexate is very similar at the two sites,
suggesting that the tumour is able to retain its specific sensitivity to cytotoxic
agents while growing at the cheek pouch.
From this it might be inferred that the response ofhuman tumours to cytotoxic
drugs is unlikely to be altered by transplantation to the hamster cheek pouch.
However, although the present results suggest this, the tumour-host relationship
in the wall of the cheek pouch is at best an unnatural union, and a variety of
factors, both known and unknown, could operate to invalidate any clinical predic-
tions made from cytotoxic studies at this site. It is known, for example, that
animals of different species may vary in their sensitivity to the toxic effects of
cytotoxic agents. This suggests that the metabolic processes involved in the
breakdown and excretion of these drugs are not always identical. Therefore, in
species as widely different as man and the hamster, there must always be the
possibility that some drugs are metabolised along different pathways, with the
result that findings obtained from cytotoxic studies may not always be strictly
comparable. It is likely, too, that the complex nutritional requirements of some
human tumours may not be met at the cheek pouch. This could, in turn, perhaps
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lead to alterations in the metabolic state of the transplanted tumour cells, with
changes in their sensitivity to cytotoxic agents.
Therefore only a direct comparison of the response of various human tumours
to a variety of cytotoxic drugs at the hamster cheek pouch and in man can
establish with absolute certainty that the response ofhuman tumour cells to cyto-
toxic agents is unchangedbytransplantation. Ifthis couldbedonethewaywould
be clearforthe use ofthe cheek pouchtechnique as apractical methodofpredicting
the sensitivities of human tumours to cytotoxic drugs.
SUMMARY
The effects of nitrogen mustard and methotrexate on Walker 256 tumour
growing on the cheek pouch of the hamster and subcutaneously in the rat have
been compared. It has been noted that the response ofthe tumour to comparable
doses of the drugs is similar in the two animals, suggesting that tumours may
retain their specific sensitivities to cytotoxic drugs when growing heterologously
at the hamster cheek pouch.
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